Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboxymethylpachymaran (CMP) is a water-soluble polysaccharide created by the carboxymethylation of pachymaran, which is extracted from the sclerotium of the fungus *Poria cocos* (also known as Fuling). [2] This modification enhances its water solubility and biological activity. [10] Research indicates that CMP possesses various physiological effects, including immunomodulatory, anti-tumor, antioxidant, and anti-inflammatory activities. [2, 3] It has been shown to inhibit the proliferation of several cancer cell lines in vitro, such as HepG-2, HT-29, and MCF-7. [2, 5] The mechanism is believed to involve immune regulation, such as increasing the secretion of cytokines like IFN-γ and IL-2. [2] In a clinical trial, it is being studied as an oral nutritional supplement to improve the nutritional status and quality of life for nasopharyngeal carcinoma patients undergoing radiation and chemotherapy. The trial is sponsored by Guangzhou Enternutr Biotechnology Co, Ltd.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylpachymaran.